Macrogen Asia Pacific Is Now Fully Operational in Singapore, Co-sponsoring 2 Conference Events in Oct
Published on 24th September, 2018
On 5th June 2018, Macrogen Inc., a well-established genomics services provider with customers from over 150 countries, established its Asia Pacific subsidiary, Macrogen Asia Pacific Pte. Ltd., in Singapore.
The new state-of-the-art laboratory has been fully operational since July, and is the only lab in Singapore equipped with Illumina NovaSeq6000 next-generation-sequencing systems. Located in Biopolis, the laboratory is able to process 40,000 human genomes a year. Currently, the laboratory provides whole genome sequencing (WGS), whole exome sequencing (WES) and capillary sequencing (Sanger) services. More services will be added as operations scale up. In its first quarter of operations, the laboratory has already sequenced more than 1000 samples for researchers located in hospitals, universities, research institutes and pharmaceutical companies.
The laboratory in Singapore adheres to the same rigorous quality standards established in other Macrogen laboratories and also participates in the Proficiency Testing program administered by the College of American Pathologists (CAP). Customers located in Singapore enjoy reduction in costs and time as testing is done locally, while enjoying the same high quality results that they have always expected. Regional customers also benefit from the well-developed logistics and customs clearing facilities in Singapore. Thus, this allows Macrogen Asia Pacific to be well-positioned as a sequencing partner for other companies offering complementary services in the precision medicine sector, such as customized library preparation methods or data analysis reporting algorithms.
With this initial success, Macrogen will be extending its research and development partnerships with Singapore-based clinicians and clinician-scientists. Led by Dr Christopher Wong, CEO Macrogen Asia-Pacific, Macrogen will collaborate to identify and bridge gaps between laboratory and bedside, to fully implement precision medicine in Singapore. Macrogen also has technologies in CRISPR (for DNA editing), iPSC (induced pluripotent stem cells) and bioinformatics, to accelerate advances in Singapore’s precision medicine landscape.
Macrogen is proud to be co-sponsor of 2 events in Oct and to meet our clients and partners at:
- Asia Pacific Society of Human Genetics Autumn School, which will be held at the National University of Singapore from Oct 31 to Nov 4, 2018, and
- A*STAR Biotech Fest, which will be held at the Biopolis, Singapore from Oct 31 to Nov 1, 2018.
The Macrogen team looks forward to its increased involvement in the Singapore R & D ecosystem, and facilitating the implementation of genomics testing to improve healthcare outcomes while reducing overall health management costs.